Physician profile
Hannah Sims
NPI 1952784795
$2,750.63
in general payments reported to CMS, 2019-2025
22 companies · $33.61 in 2025
The $33.61 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $634 · 2023: $1,538 · 2024: $277 · 2025: $33.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.41 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.68 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $350.66 | 2022-2023 | |
| Glaxosmithkline, LLC. | $327.65 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $231.86 | 2021-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $220.35 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $183.44 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.72 | 2023 | Xifaxan |
| Lilly USA, LLC | $144.17 | 2021-2024 | Mounjaro, Trulicity |
| Astellas Pharma US INC | $129.64 | 2021-2023 | Myrbetriq |
| Pfizer INC. | $125.87 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $92.18 | 2022-2024 | Farxiga, Breztri |
| Amgen INC. | $64.74 | 2021-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.34 | 2021-2024 | Stiolto Respimat, Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $42.97 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Axsome Therapeutics, INC. | $29.13 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $26.73 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $22.68 | 2023 | Gemtesa |
| Abbott Laboratories | $19.86 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $18.65 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $16.76 | 2021 | |
| Corcept Therapeutics | $15.28 | 2025 | Korlym |
| Lundbeck LLC | $14.27 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.